We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+56.2%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$178M
AUM Growth
+$28.4M
Cap. Flow
-$14.1M
Cap. Flow %
-7.93%
Top 10 Hldgs %
56.23%
Holding
58
New
12
Increased
14
Reduced
9
Closed
19

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$5.29M
2
TRML
Tourmaline Bio
TRML
+$4.64M
3
OCUL icon
Ocular Therapeutix
OCUL
+$3.87M
4
RVMD icon
Revolution Medicines
RVMD
+$3.84M
5
MRSN
Mersana Therapeutics
MRSN
+$3.65M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$8.54M
2
VTYX
Ventyx Biosciences
VTYX
+$7.13M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$4.31M
4
ALKS icon
Alkermes
ALKS
+$3.54M
5
REPL icon
Replimune Group
REPL
+$2.57M

Sector Composition

Rank Sector Weight
1 Healthcare 99.16%
2 Financials 0.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLMA icon
51
Olema Pharmaceuticals
OLMA
$1.05B
– –
-153,007
Closed -$1.89M
REPL icon
52
CALL
Replimune Group
REPL
$1.01B
– –
-1,000
Closed -$1.77M
REPL icon
53
Replimune Group
REPL
$1.01B
– –
-150,000
Closed -$2.57M
RZLT icon
54
Rezolute
RZLT
$452M
– –
-310,000
Closed -$409K
SNDX icon
55
Syndax Pharmaceuticals
SNDX
$1.82B
– –
-297,035
Closed -$4.31M
SRPT icon
56
CALL
Sarepta Therapeutics
SRPT
$1.77B
– –
-550
Closed -$7.58M
VTYX
57
DELISTED
Ventyx Biosciences
VTYX
– –
-205,377
Closed -$7.13M
MRNS
58
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-19,500
Closed -$157K
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Acuta Capital Partners held 58 positions worth $178M, up 19% from $149M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Acuta Capital Partners withdrew a net $14.1M in Q4 2023, closing 19 positions and reducing 9 holdings. Its most notable exit was Ventyx Biosciences, an estimated $7.13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 92% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Tourmaline Bio worth $6.07M.

  • Acuta Capital Partners's largest Q4 2023 buy was Tourmaline Bio: 231,882 shares worth $6.07M.
  • Acuta Capital Partners added most to Sarepta Therapeutics in Q4 2023, an estimated $5.29M increase.
  • Acuta Capital Partners's biggest Q4 2023 reduction was Apellis Pharmaceuticals, cutting an estimated $8.54M.
  • Acuta Capital Partners fully exited Ventyx Biosciences in Q4 2023, selling an estimated $7.13M.
  • Acuta Capital Partners's ten largest holdings make up 56% of its $178M portfolio in Q4 2023.
  • Acuta Capital Partners opened 12 new positions and closed 19 in Q4 2023.
  • Acuta Capital Partners's portfolio value rose 19% quarter-over-quarter to $178M.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.